The negative trial result for Novartis's Lp(a) cardiovascular drug is a landmark event prompting re-evaluation of the industry's heavy reliance on human genetic data for target validation. It questions if targeting a lifelong genetic risk factor is effective once a disease is established.

Developing preventative longevity drugs that gradually slow aging requires multi-decade clinical trials to prove efficacy, making development prohibitively expensive and slow. By focusing on therapies that reverse established age-related damage in populations already exhibiting phenotypes, companies can administer an intervention and measure biological improvement immediately afterward. This focus on reversal transforms long-term longevity biology into tractable, affordable clinical trial endpoints.

A critical disconnect exists in drug development: the decision to start a trial is most influenced by the number of academic publications on a target. However, this metric has no bearing on the trial's likelihood of success. The best predictor of success is actually strong human genetic evidence linking the target to the disease.

Human genetics doesn't just provide a drug target; it often specifies the therapeutic approach required. Discovering a protective loss-of-function mutation immediately tells researchers to develop an inhibitor (like an antibody or siRNA), accelerating the path from target discovery to molecule design.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.

A critical distinction for target selection is whether a target influences a disease's ongoing progression or merely a person's susceptibility to it. Since most medicines are designed to treat patients who already have a condition, the target must be involved in the active progression of the illness to have a therapeutic effect.

While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.

Novartis's LP(a) drug failed in patients with established cardiovascular disease, suggesting that the underlying vascular damage from a lifetime of exposure may be irreversible. This implies effective treatment might require intervention decades earlier, a timeline that poses significant, perhaps insurmountable, challenges for clinical trials and regulatory approval.